SoftWave Tissue Regeneration Technologies Enters Distribution Agreement With Cynosure

DMCA.com Protection Status
Keywords: 
Blog Category: 

By Industry News

SoftWave Tissue Regeneration Technologies Enters Distribution Agreement With Cynosure

ATLANTA, December 22, 2021 - SoftWave Tissue Regeneration Technologies (SoftWave TRT) announced an agreement to supply Cynosure LLC, a global leader in medical aesthetics, with its patented extracorporeal shock wave devices for distribution in the United States and Canada primarily to medical doctors and their practices.

"This agreement substantially increases doctors' and patients' access to our FDA cleared technology to accelerate healing, improve blood supply, activate connective tissue and to reduce pain and inflammation by leveraging Cynosure's impeccable reputation and extensive sales force and marketing team," says John Warlick, CEO of SoftWave Tissue Regeneration Technologies. "This agreement should quadruple our installed base over the next three years and provide extraordinary outcomes and benefits. This partnership will also allow Softwave TRT to focus our efforts on other fields of use, including Alzheimer's, reduced opioid consumption, and cardiology and wound care," he says.

SoftWave's patented technology triggers the body's biological healing response. SoftWave TRT devices offer a non-invasive procedure and require no anesthesia or numbing agents. The patented SoftWave TRT technology uses an unfocused extracorporeal shockwave (uESWT) that promotes both a physical and biological response to accelerate healing and tissue regeneration. The patented parabolic reflector produces a wider and deeper therapeutic energy zone, which results in reduced pain and increased blood supply, modulated inflammation, and stimulation, activating and recruiting resident and mesenchymal cells as described in published, peer-reviewed research.

About SoftWave Tissue Regeneration Technologies
SoftWave Tissue Regeneration Technologies is a bio-medical technology company that manufactures DermaGold, an FDA-cleared device for the treatment of diabetic foot ulcers and second-degree burn wounds.

Contact: info@softwavetrt.com or (888) 862-6162
Twitter: @SoftwaveTRT
www.softwavetrt.com

The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, HMP Global, its affiliates, or subsidiary companies.

Recommended for You

Important Notice: The contents of the website such as text, graphics, images, and other materials contained on the website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. The content is not intended to substitute manufacturer instructions. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or product usage. Refer to the Legal Notice for express terms of use.